{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:03:50Z","timestamp":1777010630412,"version":"3.51.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Eravacycline (ERV) is often used for drug-resistant gram-negative and nontuberculous mycobacteria (NTM) infections, but infusion site reactions are a potential adverse effect. We report a case of severe hypoesthesia secondary to ERV infusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 74-year-old man presented with dyspnea, shortness of breath, and hemoptysis after being treated for community-acquired pneumonia. On the basis of respiratory cultures performed several weeks before the index hospitalization, he was diagnosed with Mycobacterium chelonae pneumonia. On hospital day (HD) 2, the infectious diseases consult team, guided by susceptibilities, initiated a regimen of azithromycin, levofloxacin, and ERV 80 mg (1 mg\/kg) intravenously every 12 hours infused over 1 hour in 250 mL of normal saline. Approximately 25 minutes after the ERV infusion began, the patient reported tingling and numbness in his fingers, hands, and mouth, with shooting pain in his head. Symptoms resolved with cessation of the ERV infusion. On HD 3, the same ERV dose and volume was administered with an extended infusion time of 2 hours. The patient experienced the same reaction after 58 minutes, which ceased shortly after the infusion was stopped. Use of ERV was subsequently discontinued. The Naranjo adverse drug reaction probability scale score was 9, indicating a definite reaction. A review of the Food and Drug Administration Adverse Event Reporting System through March 2021 identified 22 ERV-associated events. Among these, 18% appear to be related to ERV infusions. Published results from phase 3 clinical trials did not document any hypoesthesia. It is unknown whether there is a correlation between concentration, dose, or infusion time and associated reactions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is a unique case of severe hypoesthesia secondary to ERV infusion leading to drug discontinuation. More data are needed to determine effective mitigation strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac098","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T12:19:42Z","timestamp":1649161182000},"page":"1146-1150","source":"Crossref","is-referenced-by-count":6,"title":["Eravacycline infusion\u2013related hypoesthesia: A case report"],"prefix":"10.1093","volume":"79","author":[{"given":"R Briley","family":"Miller","sequence":"first","affiliation":[{"name":"University of South Carolina College of Pharmacy , Columbia, SC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinsey M","family":"McClure","sequence":"additional","affiliation":[{"name":"University of South Carolina College of Pharmacy , Columbia, SC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robby G","family":"Stewart","sequence":"additional","affiliation":[{"name":"University of South Carolina College of Pharmacy , Columbia, SC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie C","family":"Shealy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Intermountain Medical Center , Murray, UT , USA"},{"name":"Department of Pharmacy, Intermountain Healthcare Telehealth Services , Murray, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnan","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Prisma Health Midlands , Columbia, SC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P Brandon","family":"Bookstaver","sequence":"additional","affiliation":[{"name":"University of South Carolina College of Pharmacy , Columbia, SC , USA"},{"name":"Department of Pharmacy, Prisma Health Midlands , Columbia, SC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"issue":"5","key":"2022070809074273400_CIT0001","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2022070809074273400_CIT0002","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciaa384","article-title":"Gram-negative bacteria with difficult-to-treat resistance: a moving target","volume":"72","author":"Al-Hasan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2022070809074273400_CIT0003","doi-asserted-by":"crossref","first-page":"e00470","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022070809074273400_CIT0004"},{"issue":"2","key":"2022070809074273400_CIT0005","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaip.2020.09.027","article-title":"Vancomycin hypersensitivity reactions documented in electronic health records","volume":"9","author":"Alvarez-Arango","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2022070809074273400_CIT0006","first-page":"e01617","article-title":"Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B","volume":"62","author":"John","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2022070809074273400_CIT0007","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2022070809074273400_CIT0008","author":"Shanmuagan"},{"key":"2022070809074273400_CIT0009","author":"Centers for Disease Control and Prevention"},{"key":"2022070809074273400_CIT0010"},{"key":"2022070809074273400_CIT0011"},{"key":"2022070809074273400_CIT0012"},{"key":"2022070809074273400_CIT0013"},{"issue":"3","key":"2022070809074273400_CIT0014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2022070809074273400_CIT0015"},{"key":"2022070809074273400_CIT0016"},{"issue":"6","key":"2022070809074273400_CIT0017","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2022070809074273400_CIT0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac098\/43502480\/zxac098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/14\/1146\/44469096\/zxac098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/14\/1146\/44469096\/zxac098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T09:07:59Z","timestamp":1657271279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/14\/1146\/6563268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":18,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,4,4]]},"published-print":{"date-parts":[[2022,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac098","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,15]]},"published":{"date-parts":[[2022,4,4]]}}}